Merck (MRK) Stock May Be 38% Undervalued Following Melanoma Vaccine Results
Merck (MRK) Stock May Be 38% Undervalued Following Melanoma Vaccine Results Simply Wall Street
Covered in this story
Analyst targets on Merck & Co.
- RBC Capital Markets: $145 → $145 by Oct 2027 · Sector Perform via MarketBeat
- Cantor Fitzgerald: $142 → $145 by Oct 2027 · Neutral via MarketBeat
- Morgan Stanley: $143 → $177 by Oct 2027 · Overweight via MarketBeat
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $MRK yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Merck & Co. →Dalsna Finance is currently tracking 27 stories mentioning Merck & Co., the earliest published 12 Jun 2026.
Summary aggregated from Simply Wall Street's public RSS feed. The full reporting belongs to Simply Wall Street — please read it on their site.